SOLANA BEACH, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that Professor Saoirse O’Sullivan will be presenting new preclinical data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society. The conference is being held from June 4-6, 2024, in Notti ...

SOLANA BEACH, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced Dr. Andrew Yates presented new pre-clinical data on ART12.11 at the CT-CANN24 conference which is being held May 29-30, 2024 at the Hilton London Canary Wharf in London, UK. The presentation, titled "An Aqueous S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 or ☐ TRANSITION REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-38951 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada (State or ...

SOLANA BEACH, Calif., May 13, 2024 (GLOBE NEWSWIRE) --  Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported financial and operating results for the three months ended March 31, 2024 and provided a business update. "Our entire clinical and preclinical development portfolio is progressing as planned," commented Gregory D ...

SOLANA BEACH, Calif., May 10, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that it will be participating in the 2024 Pharma Partnering Summit being held May 14th – 15th in San Diego, California. Gregory D. Gorgas, President and Chief Executive Officer of Artelo, is scheduled to present ...

公司介绍 - Artelo Biosciences, Inc. (ARTL)是一家专注于调节脂质信号通路以开发治疗癌症、疼痛、皮肤病和神经系统疾病的临床阶段制药公司[1] FABP7蛋白 - FABP7是一种细胞内蛋白，参与脂肪酸的摄取、运输、代谢和储存，在多种癌症中上调，并与患者预后不良相关[2] 研究方向 - Artelo Biosciences致力于进一步研究FABP抑制，包括选择性和全面的FABP抑制，旨在为癌症等严重疾病的患者提供新的治疗选择[3]

公司概况 - Artelo Biosciences是一家致力于开发调节脂质信号通路的专有治疗药物的临床阶段制药公司[4] - 公司总裁兼首席执行官将在Benzinga All Access节目中作为特邀嘉宾出席[1] 产品领域 - 公司在不同疾病和症状领域推进着广泛适用的产品候选药物组合，包括厌食症、癌症、焦虑、疼痛和炎症[4] 前瞻性陈述 - 公司的产品开发、临床和监管时间表、市场机会、竞争地位等方面的前瞻性陈述基于当前预期、估计、预测和关于公司所在行业和市场的管理层当前的信念和假设[5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 001-38951 Artelo Biosciences, Inc. (Exact name of registrant as specified in its charter) | --- | |------------ ...

公司背景 - Artelo Biosciences是一家专注于调节脂质信号通路以开发治疗癌症、疼痛和神经疾病的临床阶段制药公司[1] 创新挑战赛 - Artelo Biosciences被选为Johnson & Johnson创新挑战赛的决赛选手，将在美国圣地亚哥展示其ART26.12的临床前皮肤研究[2] ART26.12计划 - 公司的ART26.12计划针对FABP5靶点，可能适用于多种疾病，包括化疗诱导的周围神经病变和皮肤病[3]

公司研究成果 - Artelo Biosciences, Inc.宣布了一项新研究成果，该研究成果发表在同行评议的《疼痛杂志》上，题为“一种新型FABP5抑制剂ART26.12的发现和临床前评估，对奥沙利铂诱导的周围神经病变具有有效性”[1] - ART26.12是一种FABP5抑制剂，用于治疗化疗诱导的周围神经病变（CIPN），在临床前安全性研究中，ART26.12显示出最小的非靶效应、高口服生物利用度，并且在每天1000毫克/千克的给药下没有观察到不良影响水平（NOAEL）[1][2] 市场前景 - 全球神经病性疼痛市场估计价值为76亿美元，显示出对一种有潜力提供非阿片类止痛缓解的创新疗法的需求。Artelo已在疼痛性神经病变进行了多项临床前研究，其中后两者尚无FDA批准的治疗方法。公司此前与美国食品和药物管理局进行了积极的临床前新药（IND）会议，并计划在2024年上半年提交ART26.12的IND[3] FABP抑制剂 - FABP（脂肪酸结合蛋白）是一类内细胞蛋白，负责携带内源性大麻素和脂肪酸等脂质。ART26.12是Artelo公司的主要FABP抑制剂，是一种有效的、选择性的FABP5抑制剂，正在开发为一种新型的、外周作用的、非阿片类、非类固醇类镇痛药物，计划首先进行化疗诱导的周围神经病变的临床研究。公司的大量小分子FABP抑制剂已显示出对某些癌症、神经病性和疼痛性疾病以及焦虑症的治疗前景[4]